CORT vs. AXSM, RARX, GBT, HRMY, TARO, JAZZ, PRGO, SUPN, PCRX, and NKTR
Should you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Axsome Therapeutics (AXSM), Ra Pharmaceuticals (RARX), Global Blood Therapeutics (GBT), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Nektar Therapeutics (NKTR). These companies are all part of the "medical" sector.
Axsome Therapeutics (NASDAQ:AXSM) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Axsome Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Axsome Therapeutics presently has a consensus price target of $122.08, indicating a potential upside of 69.37%. Corcept Therapeutics has a consensus price target of $44.30, indicating a potential upside of 43.13%. Given Corcept Therapeutics' higher probable upside, research analysts plainly believe Axsome Therapeutics is more favorable than Corcept Therapeutics.
Corcept Therapeutics received 101 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.70% of users gave Corcept Therapeutics an outperform vote while only 68.77% of users gave Axsome Therapeutics an outperform vote.
In the previous week, Corcept Therapeutics had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 20 mentions for Corcept Therapeutics and 12 mentions for Axsome Therapeutics. Corcept Therapeutics' average media sentiment score of 0.77 beat Axsome Therapeutics' score of 0.37 indicating that Axsome Therapeutics is being referred to more favorably in the media.
Corcept Therapeutics has a net margin of 22.38% compared to Corcept Therapeutics' net margin of -118.07%. Axsome Therapeutics' return on equity of 24.19% beat Corcept Therapeutics' return on equity.
Corcept Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Corcept Therapeutics beats Axsome Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Corcept Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corcept Therapeutics Competitors List
Related Companies and Tools
